Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DNA2 | P51530 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307775 | 0.88 | KDM4E (0.49) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL11258062 | 0.86 | CSNK2A1 (0.52) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL13484134 | 0.86 | CSNK2A1 (0.56) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL12639377 | 0.86 | KDM4E (0.47) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL10760134 | 0.83 | KDM4E (0.45) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL10756931 | 0.83 | KDM4E (0.45) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL5794312 | 0.82 | KDM4E (0.44) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL400105 | 0.81 | ALDH1A1 (0.63) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL7081618 | 0.81 | CSNK2A2 (0.60) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL10768287 | 0.81 | CSNK2A2 (0.44) | KDM4ECSNK2A2CSNK2BCSNK2A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2258784-A | — | — | None | — | — | JP | disclosed |
| JP-60190777-A | — | — | None | — | — | JP | disclosed |
| JP-60006684-A | — | — | None | — | — | JP | disclosed |
| JP-59204194-A | — | — | None | — | — | JP | disclosed |
| WO-2024242111-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING NEUROPATHIC PAIN | 国立大学法人大阪大学 | 2024-11-28 | — | — | WO | disclosed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2205586-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SuperGen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-1990006922-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACID DERIVATIVES | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1990-06-28 | — | — | WO | disclosed |
| EP-0329719-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACID DERIVATIVES | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1989-08-30 | — | — | EP | disclosed |
| US-4840956-A | TREATING GRAM-POSITIVE BACTERIA | WARNER-LAMBERT COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
| WO-1988010253-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACID DERIVATIVES | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1988-12-29 | — | — | WO | disclosed |
| US-4735949-A | BROAD SPECTRA; GRAMPOSITIVE BACTERIA; BURN INJURIES | WARNER-LAMBERT COMPANY (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0195135-A1 | A process for the preparation of quinoline carboxylic acid derivatives | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1986-09-24 | — | — | EP | disclosed |
| JP-S60190777-A | OPTICAL ACTIVE 6,8-DIFLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYLQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1985-09-28 | — | — | JP | disclosed |
| JP-S606684-A | 7-HOMOPIPERAZINE-SUBSTITUTED-6,8-DIFLUORO-4-OXO-1,4- HYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1985-01-14 | — | — | JP | disclosed |
| JP-S59204194-A | 7-DIAZABICYCLOALKANE-SUBSTITUTED-6,8-DIFLUORO-4-OXO-1,4- DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-11-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | KDM4E 65/4885CSNK2A2 1505/4885CSNK2B 1731/4885 |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | KDM4E 65/4885CSNK2A2 1505/4885CSNK2B 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.